Addressing Motor Dysfunction by a Selective α6-Containing Nicotinic Receptor Antagonist

In the striatum, presynaptic α6-containig nicotinic receptors are crucially involved in the modulation of dopamine release. CVN417, a novel selective antagonist at this receptor subtype, attenuates motor dysfunction in a Parkinson’s disease-relevant animal model, suggesting, for this pathology, a th...

Descripción completa

Detalles Bibliográficos
Autores principales: Bolchi, Cristiano, Pallavicini, Marco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2023
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10641822/
https://www.ncbi.nlm.nih.gov/pubmed/37852222
http://dx.doi.org/10.1021/acs.jmedchem.3c01817
_version_ 1785146838051979264
author Bolchi, Cristiano
Pallavicini, Marco
author_facet Bolchi, Cristiano
Pallavicini, Marco
author_sort Bolchi, Cristiano
collection PubMed
description In the striatum, presynaptic α6-containig nicotinic receptors are crucially involved in the modulation of dopamine release. CVN417, a novel selective antagonist at this receptor subtype, attenuates motor dysfunction in a Parkinson’s disease-relevant animal model, suggesting, for this pathology, a therapeutic strategy that could greatly profit from the restricted localization of α6* nicotinic receptors in the brain.
format Online
Article
Text
id pubmed-10641822
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-106418222023-11-15 Addressing Motor Dysfunction by a Selective α6-Containing Nicotinic Receptor Antagonist Bolchi, Cristiano Pallavicini, Marco J Med Chem In the striatum, presynaptic α6-containig nicotinic receptors are crucially involved in the modulation of dopamine release. CVN417, a novel selective antagonist at this receptor subtype, attenuates motor dysfunction in a Parkinson’s disease-relevant animal model, suggesting, for this pathology, a therapeutic strategy that could greatly profit from the restricted localization of α6* nicotinic receptors in the brain. American Chemical Society 2023-10-18 /pmc/articles/PMC10641822/ /pubmed/37852222 http://dx.doi.org/10.1021/acs.jmedchem.3c01817 Text en © 2023 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by/4.0/Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Bolchi, Cristiano
Pallavicini, Marco
Addressing Motor Dysfunction by a Selective α6-Containing Nicotinic Receptor Antagonist
title Addressing Motor Dysfunction by a Selective α6-Containing Nicotinic Receptor Antagonist
title_full Addressing Motor Dysfunction by a Selective α6-Containing Nicotinic Receptor Antagonist
title_fullStr Addressing Motor Dysfunction by a Selective α6-Containing Nicotinic Receptor Antagonist
title_full_unstemmed Addressing Motor Dysfunction by a Selective α6-Containing Nicotinic Receptor Antagonist
title_short Addressing Motor Dysfunction by a Selective α6-Containing Nicotinic Receptor Antagonist
title_sort addressing motor dysfunction by a selective α6-containing nicotinic receptor antagonist
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10641822/
https://www.ncbi.nlm.nih.gov/pubmed/37852222
http://dx.doi.org/10.1021/acs.jmedchem.3c01817
work_keys_str_mv AT bolchicristiano addressingmotordysfunctionbyaselectivea6containingnicotinicreceptorantagonist
AT pallavicinimarco addressingmotordysfunctionbyaselectivea6containingnicotinicreceptorantagonist

Ejemplares similares